Empiric/pre-emptive anti-Candida therapy in non-neutropenic ICU patients.
The potential of the systemic antifungal treatment of non-immunocompromised patients with sepsis, extra-digestive Candida colonization and multiple organ failure is unknown, although it represents three out of four antifungal treatments prescribed in intensive care units. It may allow an early treatment of invasive fungal infection at incubation phase, but exposes patients to unnecessary antifungal treatments with subsequent costs and antifungal selection pressure. As early diagnostic tests for invasive candidiasis are still considered insufficient, the potential of this strategy needs to be demonstrated by a randomized controlled trial. Such a trial is currently ongoing.
INSERM IAME, UMR 1137, F-75018 Paris France ; Paris Diderot University IAME, UMR 1137, Sorbonne Paris Cité, F-75018 Paris France ; AP-HP, Bichat Hospital, medical and infectious diseases ICU F-75018 Paris France.
Jean-François
JF
Timsit
AP-HP, Bichat Hospital, medical and infectious diseases ICU F-75018 Paris France.
Sarah
S
Chemam
INSERM IAME, UMR 1137, F-75018 Paris France ; Paris Diderot University IAME, UMR 1137, Sorbonne Paris Cité, F-75018 Paris France ; Joseph Fourier (Grenoble 1) University, Albert Bonniot institute U 823, Grenoble, F-38000 France.
Sébastien
S
Bailly